Journal of Practical Hepatology ›› 2023, Vol. 26 ›› Issue (3): 428-431.doi: 10.3969/j.issn.1672-5069.2023.03.032

• Hepatic cysts • Previous Articles     Next Articles

Comparison of anhydrous ethanol and lauromacrogol sclerotherapy under ultrasound guidance in the treatment of patients with simple hepatic cysts

Zhang Qiong, Chen Shiying, Xia Wei   

  1. Department of Ultrasound, Ezhou Hospital of Traditional Chinese Medicine, Ezhou 436000, Hubei Province, China
  • Received:2022-06-29 Online:2023-05-10 Published:2023-05-08

Abstract: Objective The aim of this study was to compare the efficacy of anhydrous ethanol and lauromacrogol sclerotherapy under ultrasound (US) guidance in the treatment of patients with simple hepatic cysts (SHC). Methods A total of 97 patients with SHC were encountered in our hospital between January 2019 and October 2021, and were randomly divided into two groups, receiving lauromacrogol (n=49) or anhydrous ethanol (n=48) for sclerotherapy under US guidance. All the patients were followed-up for six months. Serum C-reaction protein (CRP), cortisol (Cor) and norepinephrine (NE) levels were detected by ELISA. Results At the end of six month follow-up, the effective rates in the two groups were not significantly different (98.0% vs. 98.0%, P>0.05); two days after operation, the peripheral white blood cell counts, red blood cell counts and platelet counts in patients with lauromacrogol sclerotherapy were(4.9±0.9)×109/L, (4.4±0.9)×1012/L and (118.8±16.5)×109/L, not significantly different as compared to [(5.1±1.1)×109/L, (4.6±0.7)×1012/L and (120.5±22.4)×109/L, respectively, P>0.05] in patients with ethanol sclerotherapy; serum Cor, CRP and NE levels in lauromacrogol-treated patients were (231.6±34.5)ng/mL, (11.5±1.7) mg/L and (257.6±31.6)ng/mL, also not significantly different compared to [(233.7±30.6)ng/mL,(12.0±2.0)mg/L and (260.2±33.5)ng/mL, respectively, P>0.05] in ethanol-treated patients; after operation, the incidence rates of abdominal distention and pain, nausea and vomiting, drunkenness response, and needle tract bleeding in lauromacrogol-treated patients were 18.4%, 24.5%, 0.0% and 2.0%, significantly lower than 43.8%, 52.1%, 22.9% and 16.7%(P<0.05) in ethanol-treated patients. Conclusion The clerotherapy with anhydrous ethanol or lauromacrogol under US-guidance in dealing with patients with SHC is safe and efficacious, and the application of lauromacrogol might have relatively fewer side effects as compared with anhydrous ethanol.

Key words: Simple hepatic cyst, Ultrasound guidance, Anhydrous ethanol, Lauromacrogol, Sclerotherapy